BTBP(SH:600161)2017-07-14 16:00Financial Performance - The company expects a net profit attributable to shareholders for the first half of 2017 to increase by approximately 876% compared to the same period last year (statutory disclosure data) and by about 849% compared to the restated data [3]. - The net profit attributable to shareholders for the same period last year was 96.93 million yuan (statutory disclosure data) and 99.61 million yuan (restated data) [4]. - The net profit attributable to shareholders for the reporting period was 218.62 million yuan, reflecting a growth of 16.93% compared to the statutory disclosure data and 15.28% compared to the restated data [5]. Revenue Growth - The company's blood products business revenue and net profit both maintained growth, with operating revenue of 694.39 million yuan, an increase of 13.95% compared to the same period last year (statutory disclosure data) and 7.81% compared to the restated data [5]. Investment Income - The company realized a pre-tax investment income of 782 million yuan from the transfer of 100% equity in Beijing Beisheng Research Biological Products Co., Ltd. and 51% equity in Changchun Qijian Biological Products Co., Ltd. [5].